View Archive

Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Virtual Hot Seat™: How the Experts Treat HER2+ Breast Cancer Across Lines of Care

Virtual Hot Seat™: How the Experts Treat HER2+ Breast Cancer Across Lines of Care

Thursday, May 13, 2021

Live, Interactive Webcast!

7:30 PM to 8:30 PM EDT


The use of adjuvant HER2-targeted therapy has dramatically improved outcomes for patients with early-stage HER2+ breast cancer. More recently, dual targeting, extended therapy, and adjuvant treatment of patients with residual disease following neoadjuvant therapy have further improved survival in the early-stage setting. Advances in the metastatic setting and the availability of effective regimens have now extended median overall survival times to nearly 5 years. Recent phase 3 data have led to the approval and introduction of a new antibody-drug conjugate and a regulatory submission for a tyrosine kinase inhibitor (TKI)-based regimen for patients with previously treated disease, further improving the outlook for patients diagnosed with HER2+ breast cancer. Now more than ever, application of all these new data to optimize treatment sequencing for these patients represents a major educational gap for oncologists.

This Virtual Hot Seat is an interactive, game-style, live webcast designed to aid clinicians in assessing the wealth of emerging data in treating HER2+ breast cancer, choosing appropriate treatment based upon patient and disease characteristics, and applying novel management strategies to their practices to improve the care of patients across the disease continuum.

Participants will be able to select which expert from the panel will face the “hot seat” to answer each of the series of challenging clinically relevant questions. This highly engaging format will provide a unique opportunity for oncologists and other health care professionals to learn from and interact with leading experts, increase their clinical knowledge, apply new data to practice, and, ultimately, improve patient outcomes.

Benefits of Attending

  • Participate in the action and steer the course of the webcast by selecting which faculty you want to see in the hot seat to answer each of the challenging questions
  • Experience the intensity of the rapid-fire questions and concise responses and follow-up discussion from the expert panel

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Target Audience

This educational program is intended for medical oncologists and other oncology health care professionals involved in the treatment of breast cancer. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with breast cancer are also invited to attend.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Determine individualized treatment strategies for patients with early-stage or advanced/metastatic HER2+ breast cancer based on current data and emerging evidence
  • Assess the impact of emerging data as well as recent approvals on evolving standards of treatment for patients with HER2+ breast cancer brain metastases
  • Discuss emerging evidence on investigational strategies for patients with HER2+ breast cancer as well as their potential implications
  • Devise strategies to optimize treatment outcomes among patients who receive HER2-targeted therapy for breast cancer, including methods to mitigate the impact and manage treatment-related adverse events

Hot Topics

  • Navigate challenges with interpreting HER2 test results
  • Learn how to sequence HER2-targeted treatment in the (neo)adjuvant settings
  • Manage treatment of brain metastases in patients with HER2+ breast cancer
  • Optimize outcomes with antibody-drug conjugates for treatment of HER2+ metastatic breast cancer

Program Chair

Sara A. Hurvitz, MD, FACP
Sara A. Hurvitz, MD, FACP
Professor of Medicine
Director, Breast Cancer Clinical Trials Program
Division of Hematology-Oncology
David Geffen School of Medicine, UCLA
Medical Director, Clinical Research Unit
Jonsson Comprehensive Cancer Center
Santa Monica, CA


2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

Meeting information is accurate at the time of posting.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information


Calendar of Events
Filter By